Tandem mass spectrometry screening is mainly for genetic metabolic diseases, which refers to the screening of metabolic diseases of amino acids, organic acids and fatty acids in children during the neonatal period. Tandem mass spectrometry screening is more efficient and can screen for dozens of metabolic diseases with a single drop of blood, and can intervene in time to prevent mental and physical developmental disorders before clinical symptoms of the disease appear, which can prevent dementia or prevent intellectual impairment and death in children. Tandem mass spectrometry differs from ordinary screening in that what is normally referred to as screening is a test that can only screen for one disease. Tandem mass spectrometry screening, on the other hand, is a test that can detect dozens of genetic metabolic diseases with a single drop of blood.